Risk for Cancer With Glucagon-Like Peptide-1 Receptor Agonists and Dual Agonists

Dec 8, 2025Annals of internal medicine

Cancer risk linked to glucagon-like peptide-1 receptor activators and combined activators: A systematic review and meta-analysis

AI simplified

GLP-1 TherapiesGLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Full Text

Full text is available at the source.
View full text (PDF) ↗View full text (XML) ↗

Related papers

Oct '25
Tirzepatide treatment for adults with obesity
cited by 3 papers
systematic review
Sep '25
Effect of lifestyle changes and GLP-1 drugs on weight and heart health markers in people with overweight or obesity
top 2% journal
cited by 9 papers
journal article
Feb '25
GLP-1 receptor drugs for people with diabetes and long-term kidney disease
cited by 10 papers
systematic review
Nov '22
Folic acid supplements and malaria risk and severity in people using antifolate malaria drugs in affected areas
cited by 19 papers
systematic review
Oct '25
Liraglutide treatment for adults with obesity
cited by 2 papers
systematic review
Oct '25
Semaglutide treatment for adults with obesity
cited by 4 papers
systematic review
Apr '25
Real-world use, benefits, and side effects of new weight-loss treatments based on GLP-1 receptor activators
top 5% journal
cited by 81 papers
journal article
Jul '24
Glucagon-Like Peptide 1 Receptor Agonists and Risk of 13 Obesity-Related Cancers in People with Type 2 Diabetes
top 2% journal
cited by 217 papers
research support, n.i.h., extramural
Oct '21
Comparing diabetes drugs for people with heart disease: a network analysis of DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT-2 inhibitors
cited by 41 papers
systematic review

Featured in

GLP-1 TherapiesGLP-1 TherapiesIssue #15
Analysis of 2.2 million patients finds GLP-1 drugs reduced liver cancer risk by 42%
↗

what lands in your inbox each week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #28
Semaglutide linked to 74-fold higher risk of vision-threatening eye condition
6 days ago3 studies
issue #27
GLP-1 drugs linked to 18% lower risk of substance use disorders in 524,817 veterans
1 week ago7 studies
issue #26
86.5% of patients on semaglutide or tirzepatide lost at least 5% of body weight at 6 months in Medicaid study
2 weeks ago7 studies
issue #25
GLP-1 drugs linked to 20% lower dementia risk in diabetic kidney patients
3 weeks ago7 studies
issue #24
Tirzepatide beats semaglutide for weight loss by 6.1% in head-to-head comparison
4 weeks ago7 studies
issue #23
Bariatric Surgery vs. GLP-1s for cardiovascular risk
5 weeks ago7 studies
issue #22
GLP-1 drugs linked to better pregnancy rates in PCOS women and reduced cancer risk in diabetes patients
6 weeks ago7 studies
issue #21
GLP-1 drugs may fight addiction, and reduce alcohol consumption
7 weeks ago7 studies
issue #20
GLP-1 drugs show promise for kidney transplant patients and Alzheimer's, but may increase eye problems
8 weeks ago7 studies
issue #19
GLP-1 drugs cut heart attack risk by 22% vs competitors, but may increase vision loss risk
9 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief